Sentence examples for differences in potency of from inspiring English sources

The ideal measure of opioid use would be to report total milligrams of morphine equivalency, to capture not only differences in doses across opioid prescriptions but also differences in potency of different opioids.

Thus differences in potency of the effects of the two different mitochondrial inhibitors in two cell types correlate with the difference in mitochondrial distribution described above.

Differences in potency of this order have been reported for Bim- and Bid-induced activation of Bax, and we have observed similar differences in Bax-binding assays reported here.

Differences in potency of our stocks meant we injected 25 ng of TeNT for the main immunohistochemical studies (Sigma-Aldrich #B5002, Gillingham, UK) and 2.5 5.0 ng for electrophysiology and its associated immunohistochemistry (#190A, Quadratech Diagnostic Ltd ,Epsom, UK).

In this study the rank order of potency for β-arrestin recruitment at the ETA (ET-1 ≥ ET-2 > > ET-3) and ETB (ET-1 = ET-2 = ET-3) receptors was as expected and there was no obvious major differences in potency of ETs when comparing with G protein-mediated constrictor assays in human vessels.

For individual subjects there were differences in potencies of standardised extracts of pollen from virus-free and virus-infected plants as assessed by skin testing, though a consistent pattern was not established for the group of 15 subjects.

For MMP-cliffs, a difference in potency of at least two orders of magnitude between cliff-forming compounds was set as a potency difference criterion.

Sunitinib, a multi-kinase inhibitor with FLT3 but not JAK2 activity, showed a 14-fold difference in potency of MV4-11-P compared with MV4-11-R.

The difference in potency of 24F4A versus 24F4A-ef was not due to a difference in signaling downstream of BDCA2 engagement as 24F4A and 24F4A-ef were equally capable of inducing phosphorylation of Syk and PLCγ2 (Fig 4G).

The differences at T=0 are not due to enrollment mistakes, but to: 1) the difference in potency of the drug used (ie, the effect of statins being more evident than the one exerted by ezetimibe) and 2) the subjects of the Berberol® alone group were still untreated at T=0.

Recently, Paolini et al. 6 mapped the human pharmacological interaction network using the definition that two proteins interact if they bind at least 10% of shared compounds with a difference in potency of only 10-fold below an activity cutoff of 10 μM, and applied it in network analysis of drug –target interactions associated with asthma.